Proliferation News and Research

RSS

Gene alterations in WNT pathway may increase CRC risk in younger patients

While increased screening continues to drive down overall colorectal cancer rates, the rate of colorectal cancer in patients under age 50 is increasing, and the disease is commonly more aggressive in these young patients.

6 Jun 2016

Researchers prove existence of olfactory receptor in pigment-producing skin cells

Researchers at Ruhr-Universität Bochum were the first ones to prove the existence of an olfactory receptor in pigment-producing cells in human skin, the so-called melanocytes. The team headed by Prof Dr Dr Dr habil. Hanns Hatt demonstrated that the violet-like scent Beta-Ionone can activate the receptor.

4 Jun 2016

Mayo study finds mechanism by which Pten safeguards against tumor formation

Pten (short for phosphatase and tensin homolog) is a tumor suppressor that is defective in about 20-25 percent of all patients with cancers. Mayo Clinic researchers now have discovered that Pten safeguards against tumor formation by keeping chromosome numbers intact when a cell splits into two daughter cells.

3 Jun 2016

Researchers detect vascular matrix stiffening during early stages of pulmonary hypertension

Pulmonary hypertension is an abnormal elevation of pressure in the pulmonary circulation that results in stress on the heart and remodeling of blood vessels in the lung.

3 Jun 2016

Fasnall drug appears to inhibit tumor growth by promoting cancer cell death

A promising new compound appears to impede a process that fuels breast cancer in mice, a discovery that could have implications in the treatment of a host of cancers.

3 Jun 2016

Gut microbe's metabolite butyrate hampers intestinal repair from IBD

Intestinal stem cells are among the most rapidly dividing cells in the body, busily creating new cells to replace the ones that are constantly being sloughed off. But unlike stem cells elsewhere in the body, those in the intestine are hidden away, and for good reason, it turns out.

3 Jun 2016

Scientists reveal how ER+ breast cancer uses cholesterol-based molecule to evade anti-hormone treatments

New research funded by Breast Cancer Now has identified how the most common breast cancers could be using a cholesterol-based molecule to evade standard anti-hormone treatments, causing patients’ disease to return.

2 Jun 2016

Metabolic characteristics of CRPC may open new avenues for treatment

Advanced prostate cancer is usually treated by removing androgen, the male hormone that helps it grow. Although initially effective, this treatment often leads to the tumor becoming castration resistant- a lethal condition.

27 May 2016

Modern day wearable technology may impact daily life, health care system

With the rapid proliferation of smart mobile devices, and the subsequent increase in data that is being gathered, the challenge is: how do we harness it?

26 May 2016

TSRI scientists discover new method for harnessing venoms for therapeutic use

There are lessons to be learned from venoms. Scorpions, snakes, snails, frogs and other creatures are thought to produce tens or even hundreds of millions of distinct venoms. These venoms have been honed to strike specific targets in the body.

26 May 2016

Common pain and anti-inflammation drugs may slow cancer growth

Scientists from the Florida campus of The Scripps Research Institute have found that one of the most widely prescribed pain and anti-inflammation drugs slows the growth rate of a specific kind of cancer in animal models and suggests the medication could have the same effect on other types of tumors.

26 May 2016

Combining vitamin A with chemotherapy may offer promise for pancreatic cancer treatment

Around 8,800 people in the UK are diagnosed with pancreatic cancer each year. It is known as the UK's deadliest cancer, with a survival rate of just 3 per cent. Chemotherapy and radiotherapy alone are relatively unsuccessful in treating the disease, and while surgery to remove the tumour offers the best chance of survival, most patients are diagnosed when the cancer has already spread to other organs.

25 May 2016

AKR1C3 enzyme could be promising therapeutic target for managing CRPC, AML

Prostate cancer is the second leading cause of mortality among American men with the highest incidence rate of all cancers reported in the U.S. Male sex hormones testosterone (T) and 5α-dihydrotestosterone (5α-DHT) promote prostate cancer progression.

19 May 2016

Flavopiridol drug could be effective strategy to impair brain cancer growth

Glioblastoma, the most common form of brain cancer is a deadly disease for which at present there is no cure. Now, researchers have published research results that show how repurposing the old drug flavopiridol could be an effective strategy to cut short sugar availability and impair cancer growth.

19 May 2016

Maintaining balance of P1 and P2 isoforms vital for reducing colon cancer, colitis risk

Inflammatory bowel disease (IBD), of which Crohn's disease and ulcerative colitis are the main types, is on the increase in the United States, affecting more than 1.6 million people and explaining perhaps the increase in advertisements offering treatments and cures.

18 May 2016

High levels of secretin hormone may play vital role in management of chronic liver diseases

High levels of a digestive hormone called secretin may play an important role in the management of certain chronic liver diseases, according to new research published in the journal Hepatology. These findings could result in new ways to treat cholestatic liver diseases, a condition that impairs the movement of bile, the fluid produced by the liver to digest fats.

18 May 2016

Targeting ERK and compensatory pathways with drug inhibitors halts colorectal cancer growth

While investigating a potential therapeutic target for the ERK1 and 2 pathway, a widely expressed signaling molecule known to drive cancer growth in one third of patients with colorectal cancer, University of California San Diego School of Medicine researchers found that an alternative pathway immediately emerges when ERK1/2 is halted, thus allowing tumor cell proliferation to continue.

18 May 2016

Biovica acquires cSens AB - creating opportunities for solving cancer diagnostic challenges

Biovica has acquired cSens AB, a company that has developed a PCR-based platform for the analysis of serum thymidine kinase (TK) enzyme activity, which correspond to tumor proliferation and cancer aggressiveness.

18 May 2016

Study shows inhibition of SHP-2 enzyme can diminish lupus symptoms

Researchers at Beth Israel Deaconess Medical Center have identified an enzyme that is significantly elevated in mouse models of systemic lupus erythematosus and in blood samples of patients with lupus.

17 May 2016

FDA approves additional indication for Eisai's anticancer agent Lenvima in combo with Everolimus for advanced renal cell carcinoma

Eisai Co., Ltd. has announced that its U.S. subsidiary Eisai Inc. has received approval from the U.S. Food and Drug Administration (FDA) for an additional indication for Eisai's in-house developed novel anticancer agent Lenvima (lenvatinib mesylate) in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy.

16 May 2016

Proliferation News and Research

Gene alterations in WNT pathway may increase CRC risk in younger patients

Researchers prove existence of olfactory receptor in pigment-producing skin cells

Mayo study finds mechanism by which Pten safeguards against tumor formation

Researchers detect vascular matrix stiffening during early stages of pulmonary hypertension

Fasnall drug appears to inhibit tumor growth by promoting cancer cell death

Gut microbe's metabolite butyrate hampers intestinal repair from IBD

Scientists reveal how ER+ breast cancer uses cholesterol-based molecule to evade anti-hormone treatments

Metabolic characteristics of CRPC may open new avenues for treatment

Modern day wearable technology may impact daily life, health care system

TSRI scientists discover new method for harnessing venoms for therapeutic use

Common pain and anti-inflammation drugs may slow cancer growth

Combining vitamin A with chemotherapy may offer promise for pancreatic cancer treatment

AKR1C3 enzyme could be promising therapeutic target for managing CRPC, AML

Flavopiridol drug could be effective strategy to impair brain cancer growth

Maintaining balance of P1 and P2 isoforms vital for reducing colon cancer, colitis risk

High levels of secretin hormone may play vital role in management of chronic liver diseases

Targeting ERK and compensatory pathways with drug inhibitors halts colorectal cancer growth

Biovica acquires cSens AB - creating opportunities for solving cancer diagnostic challenges

Study shows inhibition of SHP-2 enzyme can diminish lupus symptoms

FDA approves additional indication for Eisai's anticancer agent Lenvima in combo with Everolimus for advanced renal cell carcinoma

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News